Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 5Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Leukemia 3Thalassemia 2Primary Immunodeficiency Diseases 2Multiple Myeloma 2Hemoglobinopathies 2Hematologic Neoplasms 2Fanconi Anemia 2Cytopenia 2Anemia, Sickle Cell 2Anemia, Diamond-Blackfan 2Anemia, Aplastic 2Anemia 2Uveal Melanoma 1Recurrence 1Osteopetrosis 1Neoplasms, Plasma Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1

Interventions

AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Osteopetrosis × AP 1903 reagent × Clear all
NCT02065869 2023-09-29

Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant

Bellicum Pharmaceuticals

Phase 1/2 Terminated
187 enrolled 8 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Primary Immunodeficiency Diseases, Cytopenia, Anemia, Anemia, Aplastic, Anemia, Sickle Cell, Fanconi Anemia, Hemoglobinopathies, Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Osteopetrosis, Thalassemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Anemia, Diamond-Blackfan, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡